Distributed Bio, Inc.

San Francisco, CA · Biotech · Acquired

Broadly neutralizing fully human monoclonal antivenom antibodies for treating snakebite envenoming

distributedbio.com →
Grants
$600K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
13
3 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Development of world's first fully human broad spectrum anti-snake venom$162,708
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Development of world's first fully human broad spectrum anti-snake venom$299,941
Federal grantDepartment of Health and Human Services · Phase I · Development of world's first fully human broad spectrum anti-snake venom$137,233
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1285GENETIC INTELLIGENCE——
1286BINARY GENOMICS, INC.——
1287ELIXERA, INC.——
1288Distributed Bio, Inc.——
1289PIPA LLC——
1290Aurora Oncology, Inc.——
1291RIDGELINE THERAPEUTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 13

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.